Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA® in LGS provide significant reduction in the frequency of multiple seizure types.
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Fenfluramine led to a significant reduction in drop seizures associated with Lennox-Gastaut syndrome when added to an existing anti-epileptic treatment regimen in the pivotal phase 3 study.